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Purpose: To describe results of the Amyloid, Tau, Neurodegeneration (ATN) research
framework classification in the Argentine-Alzheimer’s Disease Neuroimaging Initiative
(arg-ADNI) cohort.
Methods: Twenty-three patients withmild cognitive impairment (MCI), 12 dementia of
Alzheimer’s type (DAT), and 14 normal controls were studied following the ADNI2 pro-
tocol. Patientswere categorizedaccording topresenceor absenceof thebiomarkers for
amyloid beta (A𝛽; A: amyloid positron emission tomography [PET] scan or cerebrospinal
fluid [CSF] A𝛽42), tau (T: CSF phosphorylated-tau), and neurodegeneration (N: CSF
total-tau, fluorodeoxyglucose [FDG]-PET scan, or structural magnetic resonance imag-
ing [MRI] scan).
Results: A+T+N+ biomarker profile was identified at baseline in 91% of mild demen-
tia patients, 20% of early MCI patients, 46% of late MCI patients, and 14% of control
subjects. Suspected non-AD pathophysiology (SNAP, A-T-N+) was found in 8% of mild
dementia, 20% of early MCI, 15% of late MCI, and 7% of control subjects. Conversion
rates to dementia after 5-year follow-up were 85% in A+T+N+MCI patients and 50%
in A-T-N+ patients.
Conclusions: We present initial 5-year follow-up results of a regional ADNI based on
AD biomarkers and the ATN classification.
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1 INTRODUCTION
Aggregation of amyloid beta (A𝛽) and abnormal phosphorylated
tau deposits in neurofibrillary tangles represent the hallmarks of
Alzheimer’s disease (AD). Recent scientific advances now allowA𝛽1-42,
aswell as total (t) and hyper phosphorylated (p) tau levels to be assayed
in cerebrospinal fluid (CSF),1 and amyloid deposits to be detected on
positron emission tomography (PET) scans.2 The National Institute on
Aging (NIA) and the Alzheimer’s Association (AA) put together a task
force and applying these new technologies, developed recommenda-
tions for AD diagnosis.3,4
Jack et al. proposed a new biomarker classification based on the
ATN (amyloid, tau, neurodegeneration) systemwith the goal of provid-
ing both more accurate AD characterization and an improved under-
standing of the sequence of events leading toAD.5,6 TheNational Insti-
tute of Aging and Alzheimer’s Association (NIA-AA) has since launched
a classification as framework for AD research, both observational and
intervention-related, but not for everyday clinical practice.7 It is based
on AD biomarker profiles divided in binary categories (positive or neg-
ative) in which “A” refers to A𝛽 biomarkers (amyloid PET or CSF A𝛽42),
“T” to tau pathology biomarker (CSF phosphorylated-tau or tau PET),
and “N” a quantitative or topographic biomarker of neurodegeneration
(CSF total-tau, fluorodeoxyglucose [FDG]-PET, or structural magnetic
resonance imaging [MRI]).7,8
The objective of this studywas to evaluate the ATN research frame-
work classification for AD in the Argentine ADNI cohort and examine
its prognostic value predicting transformation rate to dementia during
5 years of prospective follow-up.
2 MATERIAL AND METHODS
Fifty-six individuals were prospectively enrolled into the Argentine
Alzheimer Disease Neuroimaging Initiative (Arg-ADNI) study cohort.2
Patients were referred from the Memory & Aging Center at FLENI
Institute for Neurological Research in Buenos Aires, Argentina, and
normal controls recruited from the community. Methods used for data
collection as well as study design have already been described in detail
elsewhere.2 Initial patient workup included a structured interview,
laboratory tests, and anatomical andmolecular brain imaging. Thirteen
subjects were excluded during the follow-up (one due to cancer, one
due to psychiatric disease, four due to institutionalization, four due to
refusal to continue, and three for lack of compliance). Forty-nine par-
ticipants were included for initial assessment and 43 for the follow-up
analysis.
The study was approved by the institutional ethics committee (IRB
no.: 07/11) andwritten informed consent obtained either from partici-
pant, and/or their legal representative.
2.1 Neuropsychological assessment
Subjectswere evaluated using locally adapted validated versions of the
following tests, translated into Spanish: Mini Mental State Examina-
RESEARCH INCONTEXT
1. Systematic review: The authors reviewed the literature
using traditional sources (e.g., PubMed, Scopus, Latindex)
for the recommendation for diagnosis of pre symptomatic
Alzheimer’s disease (AD) and mild cognitive impairment
(MCI) using AD biomarkers, but not all were considered
for prediction of dementia. Jack et al. (2016) proposed a
new classification based on amyloid (A), tau (T), and neu-
rodegeneration (N).
2. Interpretation: Our objective was to describe the A/T/N
classification in the Argentine Alzheimer’s Disease Neu-
roimaging Initiaive (ADNI) cohort and the prognosis
of conversion to dementia. Our findings suggest that
MCI patients A+/T+/N+ (due to AD) or MCI patients
A−/T−/N+ (with neurodegeneration)must be recognized
for their high prognosis of dementia in a short time.
3. Future Directions: The possibility of having local results
in Latin America will allow us to add and compare what
has been obtained in developed countries and to better
characterize this pathology in amore generalized way.
tion (MMSE),8 Wechsler’s LogicalMemory Scale,9 Rey Auditory Verbal
Learning Test (RAVLT),10 BostonNaming Test,11,12 Animal Fluency and
Letter Fluency,13 Trail Making Test A and B (TMT-A, TMT-B),14 Clini-
calDementiaRating (CDR),15 Neuropsychiatric InventoryQ (NPI-Q),16
Geriatric Depression Scale (GDS),17 and Functional Assessment Ques-
tionnaire (FAQ).18
2.2 StructuralMRI analyses
All subjects underwent a 3-Tesla magnetic resonance imaging (MRI)
scan of the brain. Presence or absence of hippocampal atrophy was
classified based on the visual inspection by the radiologist (medial
temporal atrophy)19 and hippocampal reconstruction performed using
FreeSurfer v 4.3 automated volumetric output (http://surfer.nmr.
mgh.harvard.edu/).
2.3 Metabolic and amyloid PET scan (FDG and PiB)
PETwith FDGand 11C-Pittsburgh compound-B (PiB)was performed in
every subject. The FDG PET acquisition protocol was used to evaluate
parieto-temporal AD hypometabolism and the Pittsburgh compound B
PET acquisition protocol, to look for amyloid deposits in the brain. Syn-
thesis of 11C-PiB was synthetized in a GE TRACER lab FXC PROmod-
ule, and lineal color scales used to detect metabolism as well as pres-
ence and spatial distribution of cortical amyloid.
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2.4 Apolipoprotein E genotyping
Apolipoprotein E (APOE) genotyping was performed in all participants
by polymerase chain reaction (PCR) following the Hixson and Vernier
protocol as previously described,2 and the test considered positive if
one ormore 𝜀4 allele was detected (𝜀4+).
2.5 CSF AD biomarkers
CSF samples were obtained by lumbar puncture. The FLENI biomolec-
ular laboratory runs CSF biomarkers using INNOTEST (Fujirebio)
enzyme-linked immunosorbent assay kits. Cutoff values are: A𝛽42 less
than 534 pg/mL, total tau (t-tau) higher than 343.9 pg/mL, and phosfo
tau (p-tau) higher than 42.4 pg/mL.
2.6 Patient classification based on clinical data
ADNI-2 procedure manual definitions were applied for: normal con-
trols (NC), early MCI (e-MCI), late MCI (l-MCI), and dementia of
Alzheimer’s type (DAT) patients.
Cognitively normal subjects were normal subjects with baseline
MMSE8 scores between 24 and 30 points, a CDR15 score of 0. Nor-
mal memory function was documented for score above educational-
adjusted cutoffs, on the delayed recall of one paragraph fromWechsler
Memory Scale Logical Memory II.9
Early MCI subjects (e-MCI) were individuals with MMSE8 scores
between 24 and 30, a CDR15 of 0.5, an objective memory loss score
adjusted for age and education (≥16 years: 9–11; 8–15 years: 5–9;
0–7 years: 3–6) onWechslerMemory Scale (WMS) LogicalMemory II,9
and preserved activities of daily living.
Late MCI subjects (l-MCI) had MMSE8 scores between 24 and
30 (inclusive), a CDR15 of 0.5, an objective memory loss score
(≥16 years: ≤8; 8–15 years: ≤4; 0–7 years: ≤2) on theWechsler Mem-
ory Scale Logical Memory II,9 and preserved activities of daily living.
Mild dementia of Alzheimer’s type (DAT) subjects: MMSE8
scores between 20 and 26 (inclusive), a CDR15 of 1.0, meeting
NINCDS/ADRDA criteria for probable AD.20
2.7 The ATN biomarker classification
Patients were categorized according to six AD biomarkers available
at baseline in FLENI. Although every biomarker exists on a continu-
ous scale, normal versus abnormal cutoff points exist for most dis-
ease categories. Toapply theATNclassification, abiomarkerdichotomy
was used. For CSF biomarkers, cutoff values validated at FLENI were
applied in each case. For neuroimaging biomarkers, visual inspection
by two neuroradiologists, blinded to patient clinical data was applied
to establish presence or absence of A𝛽 deposits on PET with PiB and
presence or absence of parieto-temporal hypometabolism on FDG-
PET. Hippocampal atrophy was considered present on MRI if medial
temporal atrophy indexwas equal to or greater than 1.19 Thus “A” indi-
cated A𝛽 biomarker presence defined as a high ligand retention on
amyloid PET with PiB or/and A𝛽 42 in CSF levels below the specified
cut-off point. “T” corresponded to abnormal tau defined as p-tau inCSF
above established cutoff point. “N” for neurodegenerationwas defined
as either elevated CSF t-tau levels or, imaging biomarker presence as
either bilaterally parieto-temporal hypo metabolism on FDG-PET or
medial temporal region atrophy on structural MRI.19
2.8 Follow-up
Of the initial cohort totaling 56 participants, 43 completed longitudi-
nal follow-up (ie, baseline-, 12-, 30-, and 60-month visits). Conversion
to dementiawas reported inMCI patients and control individualswhen
theCDRscore changed to1.Kaplan–Meier plotswereused toestimate
survival and outcome was defined as a transition from control state
(CDR 0) or MCI (CDR 0.5) to dementia (CDR 1) during the follow-up
(dichotomous outcome). Time in this analysis corresponded toduration
of follow-up (months).
2.9 Data analysis
Statistical analyses were performed with the SPSS v19.0 (USA). Cate-
gorial variables were expressed as frequency (%) and continuous vari-
ables as the mean (SD). Normality was tested using the Shapiro–Wilk
test. The ANOVA test was used for comparisons between continuous
variables and the𝜒2 test for categorical variables. Kruskal–Wallis one-
way analysis of variance test was used if samples were not distributed
normally. For multiple comparisons, Bonferroni’s post hoc tests were
applied. Conversion proportion was estimated by Survival Kaplan–
Meier analysis. Differences between the means were considered sta-
tistically significant at P< 0.05.
3 RESULTS
3.1 Baseline characteristics of study subjects
Demographic, clinical, cognitive, and biomarker information at base-
line is summarized in Table 1 for each group. All four groups (normal
controls, e-MCI, l-MCI, and DAT patients) shared similar demographic
data (education level, age, and sex) and all subjects were white (pre-
dominantly European descent) native Spanish speakers. Globally, all
four populations were similar regarding percentage of APOE 4 carri-
ers, though slightly lower numbers were found in controls.
As expected, statistically significant difference was observed on
baseline MMSE,8 and on FAQ18 test results between normal controls
and the DAT group. No differences however were found in behavioral
symptoms (NPI-Q16 and GDS17). Mean scores on neuropsychological
assessment differed significantly among groups, with a typical contin-
uum in cognitive performance, as previously described.2
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TABLE 1 Demographic, clinical, cognitive, and cerebrospinal fluid biomarker variables at baseline
Controls e-MCI l-MCI DAT F (p) * P (<0.05)
Demographics
Number 14 10 13 12
Age (years) 70.1(8.2) 73.0(8.8) 74.8(6.3) 77.9(5.5) 2.562 (ns)
Sex (male/female) 4/10 6/4 5/8 5/7
Education (years) 14.1 (2.8) 12.8 (5.3) 14.3(4.2) 12.3 (4.0) 0.702 (ns)
APOE carrier ɛ4, % 35.7% 40% 53.8% 50% **ns
Clinical
CDR 0 0.5 0.5 1 –
MMSE 29.6 (0.8) 29.3 (0.8) 28.1 (1.4) 22.5 (3.3) 34.470 (<0.000) c, e, f
NPI-Q 0.4 (1.0) 3.8 (4.7) 5.7(7.9) 5.9 (4.7) 2.222 (ns)
GDS 1.2 (1.1) 2.3 (2.1) 2.7(2.5) 1.8 (1.7) 0.850 (ns)
FAQ 0.0 (0.0) 3.0 (3.6) 3.1(3.0) 8.3 (6.7) 6.119 (<0.005) c
Cognitive
RAVLT delay recall 8.3 (2.7) 3.6 (1.8) 2.0 (2.3) 0.4 (0.8) 29.781(<0.000) a, b, c, d, f
RAVLT recognition 13.3 (1.2) 11.3 (2.7) 8.1 (4.1) 6.0 (3.6) 11.310(<0.000) b, c, f
BNT 28.5 (2.1) 26.9 (3.2) 24.6 (4.9) 20.0 (6.2) 7.047(<0.001) c, f
SVF (animals) 22.0 (3.2) 18.5 (2.8) 17.1 (3.4) 11.8 (4.0) 17.420 (<0.000) b, c, f
FVF (“p”) 19.7 (4.4) 14.4 (6.8) 16.5 (4.0) 13.8 (5.4) 2.861 (<0.05)
Span direct 5.6 (1.2) 5.5 (1.1) 5.3 (1.0) 5.3 (1.0) ns
TMTA (seconds) 32.5 (9.7) 47.6 (20.1) 47.7 (20.8) 131.9 (121.3) 5.614 (<0.002)
TMTB (seconds) 69.1 (23.1) 150.0(125.6) 129.2(61.1) 332.1 (134.5) 17.497 (<0.000) c, f
AD Biomarkers (% positive)
A (amyloid)
A𝛽1-42 - CSF 30% 42% 64% 88% **<0.05
Amyoid PET (PiB) 14% 30% 53% 83% **<0.05
T (tau)
Phosfo-tau CSF 20% 42% 64% 86% **<0.05
N (neurodegeneration)
Left hippocampus-MRI 0% 22% 50% 56% **<0.05
t-tau CSF 10% 29% 55% 88% **<0.01
FDGPET 7% 40% 54% 100% **<0.00
eMCI, early mild cognitive impairment; lMCI, late mild cognitive impairment; DAT, dementia of Alzheimer’s type; CDR, clinical dementia rating; MMSE, Mini
Mental State Exam; NPI-Q, Neuropsychiatric Inventory; GDS, Geriatric Depression Scale; FAQ, Functional Activities Questionnaire; RAVLT, Rey Auditory
Verbal Learning Test; BNT, Boston Naming Test; SVF, Semantic Verbal Fluency (animals); PVF, Phonologic Verbal Fluency (p); TMT A and B, Trail Making Test
A and B; Rey fig, Figure of Rey.
Mean (SD); P (ANOVA) and * Bonferroni post hoc; a, controls versus eMCI; b, controls versus lMCI; c, controls versus DAT; d, eMCI versus LMCI; e, eMCI
versus DAT; f, lMCI versus DAT. ** 𝜒2.
3.2 AD biomarker results
TheATN framework in our sample providesmultiples options for defin-
ing A and N. We consider the biomarker present when at least one
method gives a positive result.
• Amyloid biomarkers (A). Amyloid PET scan was positive (A+) at
baseline in 2/14 (14%) normal controls; 3/10 subjects with e-MCI
(30%); 7/13 subjects with l-MCI (53%); and 10/12 subjects with
mildDAT (83%), with significant difference across diagnostic groups
(P < 0.05). Correlation between amyloid PET scan and A𝛽1-42 (A)
was globally 0.8 and 0.9 in DAT subjects; 4/19 (21%) subjects (two
normal controls and twoMCI subjects) were positive in A𝛽1-42 and
negative on the amyloid PET scan.
• Tau biomarker (T). Phosphorylated tau in CSF was positive (T+) in
20% of normal controls and 86% of DAT subjects.
• Neurodegeneration biomarkers (N) studied by volumetricMRI anal-
ysis of the hippocampus, FDG PET scan, and total tau in CSF
showed significant differences amongpatient groups (MCI andDAT)
and normal controls (P < 0.05) but global correlation between
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F IGURE 1 Frequency of ATN in the controls, early mild cognitive impairment, late mild cognitive impairment, and dementia of Alzheimer’s type
hippocampus volume and FDG PET scan was 0.4 and with total
tau 0.2.
Correlation between total and phosphorylated tau was 0.8 in all
populations.
Subjects were classified at baseline according to ATN classification
(Figure 1) as follows:
- Group A+T+N+: 14% (2/14) were controls, 20% (2/10) were early-
MCI, 46% (6/13) were late-MCI, and 92% (11/12) were mild DAT
patients.
- Group A-T-N+ (SNAP): 7% (1/14) were controls, 20% (2/10) were
early-MCI, 15% (2/13) were late-MCI, and 8% (1/12) were mild DAT
patients.
- Group A-T-N-: 57% (8/14) were normal controls, 40% (4/10) were
early-MCI, 23% (3/13) were late-MCI patients, but we found no
cases of mild DAT.
3.3 Follow-up subjects
Subjects were followed longitudinally (baseline, and at 12, 30, and
60months).
Of the normal control group at baseline, 1/14 (7%) and 3/14 (21%)
were diagnosed as MCI at 30 and 60 months, respectively. No normal
subject became demented.
Survival was analyzed (Kaplan–Meier) in MCI according to the ATN
classification, inwhich the outcomewas defined as transition fromMCI
to dementia during the follow-up (dichotomous outcome; see Figure 2).
Conversion to dementia was observed after 60-month follow-up in
85% (7/8) ofA+T+N+, and50% (2/4)A-T-N+patients.No cases of con-
version were identified in A+T-N- or A-T-N- patients.
4 DISCUSSION
The goal of our study was to apply the ATN classification at baseline
in an Argentine ADNI cohort and study risk of progression to demen-
tia based on biomarker results. The Memory and Aging Center from
the Instituto de Investigaciones Neurologicas FLENI, in Buenos Aires,
Argentina, was the first center in Latin America to routinely use AD
biomarkers.22-24 No significant differences were found between MCI
patient groups in cognitive functions, except for episodic memory (l-
MCI patients scored lower on delayed recall of the RAVLT), behavioral
symptoms (evaluated using NPI-Q and GDS), and functional activities
(FAQ). As previously mentioned, atrophy of the hippocampus showed
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F IGURE 2 Survival analysis of mild cognitive impairment by clinical (left side) versus biomarkers ATN (right side) classifications
progression along the classic continuum, correlating with degree of
memory loss observed in patients, from controls to e-MCI, to l-MCI, to
DAT.25
In relation to AD biomarkers, we found a statistically significant
difference in results between controls and DAT patients. PiB-PET
scans show greater disease activity levels in DAT than in either
MCI group. In agreement with published literature, 14% of nor-
mal controls presented evidence of brain amyloid deposits on PiB
PET.3
For this study, we used the biomarker-based ATN classification
system,2,3 which provides a common research framework for centers
worldwide to describe AD based on neuropathological changes, rather
than on a clinical syndrome, generating a biological rather than syn-
dromic definition of AD.7 In work previously published we applied the
new ATN classification,3 and found normal biomarker results (A-T-N-)
in 58% of clinically normal controls, 40% of e-MCI cases, and 23% of l-
MCI cases, but in no casesofmildDAT.Positivity of all threebiomarkers
(A+T+N+), the hallmark for AD, was found in this same study in 14%
of normal controls, 20% of e-MCI, 47% of l-MCI, and 91% of mild DAT
cases. Presence of neurodegeneration without amyloid (A-T-N+) indi-
catesnon-Alzheimer’s pathology, alsodefinedasSNAP (suspectednon-
Alzheimer’s pathophysiology).5 In this study SNAPwas detected in 7%
of normal controls, 20% of e-MCI, 15% of l-MCI, and 9% of mild DAT
cases, similar to results from other ADNI study centers worldwide, in
which SNAP incidence was 17% ofMCI cases and 7% of DAT cases.26
When we studied rate of progression to dementia based on clinical
classification, 10% of normal controls, 20% of e-MCI, and 46%of l-MCI
patients progressed after 2 years follow-up.24 In the late MCI group,
percentageof annual progression inour serieswashigher than the clas-
sical 5% to 10% per year described by Petersen et al. in their original
cohort.27 We therefore decided to apply the ATN classification system
that is independent of cognitive status to the MCI group as a whole
and observed that 75% of A+T+N+ patients progressed to dementia
at 30months and 85% at 60months. This rate was 50% in A-T-N+. Our
findings suggest that A+T+N+ MCI patients have worse prognosis,
but A-T-N+ MCI patients (neurodegeneration only) also present risk
of progression. We had only four A-T-N+ MCI patients, two of which
developed dementia. One was ultimately diagnosed with hippocampal
sclerosis probably due to TDP43 proteinopathy; in the second case,
although dementia of hippocampal profile was diagnosed, neuropatho-
logical findingswere inconclusive. Finally, two other patientswith amy-
loidosis but no signs of neurodegeneration (A+T-N-) have shown no
progression in 5 years of follow-up.
The new ATN classification framework used for research is impor-
tant because globally, it not only identifies patients with positive
or negative amyloid, but also others with variable combinations AD
biomarkers. Current results are more promising because MCI prog-
nosis and progression to dementia are better characterized than in
the classic clinical classification. Measuring relevant pathophysiology
in living subjects using biomarkers provides a novel approach to the
interpretation of the continuum from proteinopathy to AD as well as
of other degenerative dementias.
Diagnosis of dementia of Alzheimer’s type used to be based on clini-
cal criteria exclusively,19 but this has recently beenmodified to include
biological criteria through application of AD biomarker results.21 The
fact that the typical syndrome is neither sensitive nor specific enough
to characterize neuropathological changes of AD suggests that relying
only on cognitive symptoms is not an ideal way to defineAD.7 To better
understand the pathophysiology and to discover a treatment for AD,
we need to move toward a biological classification of neurodegenera-
tive disease.7 The AD profile is characterized by abnormal patterns in
structural (MRI) and functional (FDG-PET scan) imaging, as well as by a
signature CSF abnormality, namely abnormal levels of A𝛽1-42, total tau,
and phosphorylated-tau,28 as well as by increased amyloid uptake on
PiB-PET. In recent years, neurodegenerative diseases have undergone
a conceptual change from being distinct clinical syndromes to becom-
ing diseases related to accumulation of proteins.
In symptomatic individuals (MCI and dementia), biomarkers have
been used to refine etiological diagnosis4 and during preclinical stages
they have been used to define the AD construct.3 Petersen et al.
described mild cognitive impairment as a dementia risk construct.27
MCI can result from diseases other than AD (cerebrovascular disease,
fronto-temporal dementia, etc.). Prototypical multidomain amnestic
dementia used to clinically define AD dementia is present in 10% to
ALLEGRI ET AL 7 of 8
30% of individuals with normal amyloid PET scan and/or normal CSF
A𝛽1-42 levels, and must be therefore produced by other diseases.
29 In
late aging it is most commonly associated with multiple pathologies.30
Disease variability or final MCI prognosis risk still generate confusion
in research.31,32 Major criteria for MCI diagnosis have been proposed
by the International Working Group (IWG)33 on one hand, and by the
National Aging Institute and Alzheimer Association (NIA-AA)4 on the
other. Clinical diagnosis of MCI requires one positive AD biomarker
and is called prodromal AD by the IWG.33 Whereas one amyloid plus
one degeneration biomarker need to be present to diagnose MCI due
to AD according to the NIA-AA4 AD, biomarkers determine more pre-
cise diagnoses and better treatment monitoring.32 In a previous study,
we evaluated MCI patients23 and found an AD profile present in 18%
of controls, 64% of MCI, and 92% of DAT. SNAP was present in 11%
of controls, 6% of MCI, and 8% of DAT patients. MCI with or with-
out detectable amyloid can progress to dementia. At 2-year follow-up,
45% of patients with amyloid positiveMCI and 20% ofMCI with SNAP
had progressed to dementia.23 Constellations with conflicting CSF
biomarker findings (eg, neurodegeneration without amyloid—SNAP)
are not currently considered by IWG or NIA-AA classifications.34 In
some patients presenting the typical multidomain amnesic phenotype
used to defined probable AD, no AD tissue pathology was found.22,29
Conversely, non-amnesic syndromes may also be atypical forms of
AD, with some patients presenting fronto-temporal dementia pheno-
type due to AD.35 Analyzing degree of concordance between 11C-PiB-
PET findings and clinical diagnosis in patients from our memory clinic
we observed 72% of agreement between positive amyloid and typi-
cal clinical AD diagnosis.22 Twenty-five percent of patients present-
ing fronto-temporal phenotype had positive amyloid on PET.22 Also,
10% of patients in this cohort with lowCSF A𝛽1-42 had a negative amy-
loid PiB-PET scan.22 In the Arg-ADNI sample 21% were only positive
for CSF A𝛽1-42 levels, with 0.8 of correlation with amyloid PET scan.
This mismatch between PiB PET amyloid detection and A𝛽1-42 level
in CSF has been explained as representing different stages of amy-
loid plaque formation, because CSF A𝛽1-42 reduction has systemati-
cally been described as presenting first, and amyloid binding on PET
later.36 Correlation between neurodegeneration biomarkers was very
low, ranging from 0.2 to 0.4. This result could contribute to a better
understanding of the utility of each option. The most significant (P <
0.00) difference between the populations was observed for FDG-PET
scan results, 7% positive in normal controls, 40% to 54% in MCI, and
100% in DAT.
Limitations to this study include small initial sample size (56 sub-
jects), small sample size at 60 months (42 patients), short follow-up
(60 months), and lack of autopsy validation. Our results cannot there-
fore be generalized to all MCI patients, because the ADNI cohort was
limited to amnesic MCI phenotypes to enrich the sample with pre-
dementia AD cases. Effects of other brain pathologies associated with
increased p-tau or t-tau levels could thus have been minimized in
the ADNI cohort. Another difficulty could be the artificial borderline
biomarker value range used to define positive or negative results.
Nevertheless, despite the limitations described above, the results
are significant because FLENI is the only ADNI center in South
America applying rigorous systematic evaluation of biomarkers for AD.
The vast majority of published data is on PET and CSF results from
patients recruited from selected centers in developed countries.37
The possibility of generating results from Latin America even though
participants in this cohort were predominantly of European ances-
try, will contribute valuable information for comparison purposes with
results from developed countries, and help characterize the condition
in a more generalized manner. Some authors believe biomarker-based
research from low and middle incomes countries in developing world
regionsmight not be reliable, a concept our efforts attempt to refute.38
5 CONCLUSION
The present study provides evidence on application of ATN criteria in
a developing country from South America, currently used only in the
framework of research on AD worldwide. To the best of our knowl-
edge, this is the first AD biomarker-based report from this region with
60 months follow-up, applying the new ATN classification. Our find-
ings suggest both A+T+N+MCI patients (due to AD) and A-T-N+MCI
patients (SNAP) should be diagnosed early, because of their increased
risk of dementia transformation in a relatively short time period.
Biomarker resultswill providemoredetails onADphysiopathology and
probably represent the step forward needed to resolve pharmacologi-
cal treatment.
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